Who
Daniel Tardiff
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, CAMP4 Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $17K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Dec 2025
- Last trade
- 19 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 19 Aug 2026 | CAMP CAMP4 TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,2731,738 at $4.76 | filing |
| 19 Aug 2026filed 19 Aug 2026 | CAMP CAMP4 TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,2731,738 at $4.76 | filing |
| 1 Apr 2026filed 3 Apr 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 11 Dec 2025filed 22 Dec 2025 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,500 at $0.00 | filing |
News
Critical Analysis: Iovance Biotherapeutics (NASDAQ:IOVA) vs. CAMP4 Therapeutics (NASDAQ:CAMP)CAMP · tickerreport.com · 24 Oct 2026
0 headlines in the last 90 days name Daniel Tardiff; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.